TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06572618: Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma

Sponsor: City of Hope Medical Center · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 27 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$9,840,600

Rescue Site Savings

+$6,514,200

Unlock Full NCT06572618 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06572618 Rescue Dossier →